Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKA | O14965 | 15/20 | 0.46 |
| ▸ | AURKB | Q96GD4 | 3/20 | 0.46 |
| ▸ | RET | P07949 | 1/20 | 0.38 |
| ▸ | F2 | P00734 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | SYK | P43405 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1298385 | 0.91 | AURKA (0.49) | AURKAAURKBRETSYK | |
| SCHEMBL3244637 | 0.90 | AURKA (0.49) | AURKAAURKBRETSYK | |
| SCHEMBL1298420 | 0.87 | AURKA (0.49) | AURKAAURKBRETSYK | |
| SCHEMBL1298578 | 0.81 | DHODH (0.39) | AURKAAURKBRETSYK | |
| SCHEMBL1298492 | 0.81 | JAK2 (0.52) | AURKAAURKBRETSYK | |
| SCHEMBL1298984 | 0.81 | JAK2 (0.41) | AURKAAURKBRETSYK | |
| SCHEMBL1298875 | 0.81 | JAK2 (0.41) | AURKAAURKBRETSYK | |
| SCHEMBL1298842 | 0.81 | JAK2 (0.41) | AURKAAURKBRETSYK | |
| SCHEMBL1298726 | 0.80 | AURKA (0.50) | AURKAAURKBRETSYK | |
| SCHEMBL1299293 | 0.79 | KMT2A (0.38) | F2MAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110269740-A1 | JAK KINASE MODULATING COMPOUNDS AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORPORATION | 2011-11-03 | — | — | US | disclosed |
| WO-2010002472-A1 | JAK KINASE MODULATING COMPOUNDS AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORPORATION (US) | 2010-01-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110269740-A1 | JAK KINASE MODULATING COMPOUNDS AND METHODS OF USE THEREOF | JAK2, JAK1, JAK3 | AURKA 601/4885AURKB 507/4885RET 360/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.